What happened
Shares of the rare disease specialist Ultragenyx Pharmaceutical (NASDAQ: RARE) are having a rough session Tuesday. Specifically, the biotech's stock dropped by as much as 17% in early morning action.
The company's shares have rebounded to some degree since, but Ultragenyx's stock was still down by a hefty 13% as of 11:30 a.m. ET.
Image Source: Getty Images.
So what
What's sparking today's sell-off? Yesterday, Ultragenyx announced that it would exercise its option to acquire GeneTx Biotherapeutics for an up-front cash payment of $75 million, plus another $115 million in potential milestone-dependent payments. Through this acquisition, the biotech will add the antisense oligonucleotide therapy GTX-102 to its broad pipeline of therapies indicated for various rare diseases.
GTX-102 is currently in early-stage development for Angelman syndrome, a rare neurogenetic disorder caused by loss of function of the maternally inherited UBE3A gene. The problem -- at least from the market's perspective -- is the fact that early-stage drugs are inherently risky. Stated simply, this moody market clearly would have preferred the company hold onto this cash, rather than attempt to create long-term value for shareholders.
Now what
Investors, however, may be overreacting to this news. At present, there are no Food and Drug Administration-approved therapies for Angelman syndrome. GTX-102, therefore, could turn out to be a major revenue generator for the company within a few short years. As a result, aggressive investors might want to take advantage of today's double-digit dip.
10 stocks we like better than Ultragenyx Pharmaceutical
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Ultragenyx Pharmaceutical wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 2, 2022
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
